Celgene
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Celgene sits in the top decile of US sponsors by registered trial count (#115 of 15,742 sponsors by registered trial count).
Celgene: 308 sponsored US clinical trials, 12 recruiting.
Celgene sponsors 308 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 221 completed. 57 of these trials are in Phase 3-4 (later-stage) and 236 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma, with 11 trials.
Top-decile sponsor footprint
Celgene ranks in the top decile of sponsors by registered trial count (#115 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
221 of 282 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
308 total, page 2 of 7
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
NCT04753697
A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM
NCT04730505
A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants
NCT04839809
A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects
NCT04702464
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT04434196
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
NCT04639115
Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects
NCT04655898
Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment
NCT04573582
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
NCT04464798
A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants
NCT04560738
A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects
NCT04528290
A Study to Evaluate Effects of CC-99677 on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Participants
NCT04718636
A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
NCT04336982
A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers
NCT04350463
A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma
NCT04324840
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT04428788
Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects
NCT04373187
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
NCT04196491
A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects
NCT04297124
Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)
NCT04140305
CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
NCT04047303
Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin
NCT04231435
Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects
NCT04211545
Japanese Pharmacokinetic Bridging Study for CC-93538
NCT04096105
Bioavailability of Enasidenib (CC-90007) Sprinkle Formulation Relative to the Reference Tablet Formulation and Effect of Food on the Pharmacokinetics of Sprinkle Formulation in Healthy Adults
NCT04310527
Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites
NCT04149678
A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment
NCT03983161
Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort
NCT04097704
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
NCT04036461
Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
NCT04048876
A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer
NCT03906526
Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects
NCT03983239
A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
NCT03745222
A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects
NCT03958864
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
NCT03755518
A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
NCT03783403
Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects
NCT03824678
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects
NCT03803644
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
NCT03601078
A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects
NCT03742882
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
NCT03575351
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT03743246
Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites
NCT03665610
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
NCT03467958
Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response
NCT03694119
Drug-drug Interaction Study of Ozanimod With Pseudoephedrine to Evaluate the Effect on Blood Pressure and Heart Rate
NCT03644576
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
NCT03464097
Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A
NCT03624959
A Study to Evaluate Gluten Challenge on Immune Responses in Subjects With Celiac Disease
NCT03521180
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
NCT03486067
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 161 |
| Phase 2 | 75 |
| Phase 3 | 56 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Celgene pipeline
12 recruiting of 308 indexed (4% open); 221 completed (72%).
Phase mix: 57 late (III/IV) vs 236 early (I/II) (early-phase heavy).
Top condition: Multiple Myeloma (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Celgene: open-pipeline peers nationwide
Peers matched on 308 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Celgene sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 308 trials (± recruiting share)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 305 trials · 8% recruiting
- Allergan · 314 trials · 0% recruiting
- University of Arkansas · 318 trials · 12% recruiting
- Rush University Medical Center · 320 trials · 17% recruiting
Sponsors near 4% open enrollment (± trial volume)
- U.S. Army Medical Research and Development Command · 4% recruiting · 77 trials
- MedtronicNeuro · 4% recruiting · 51 trials
- Aldeyra Therapeutics · 4% recruiting · 26 trials
- DexCom · 4% recruiting · 26 trials
Related
What to do with this Celgene page
308 registered trials is a research-attention snapshot, not an endorsement of Celgene or any single study.
- 12 of Celgene's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Myeloma is the condition Celgene studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Myeloma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Celgene pipeline card: 308 registered trials from official public datasets.Report a data error.